Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | IGF1R | P08069 | 2/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242194 | 0.98 | ADAM17 (0.36) | PDK2ADAM17SLC2A1BACE1IGF1R | |
| SCHEMBL3243561 | 0.87 | PDK2 (0.38) | PDK2ADAM17BACE1 | |
| SCHEMBL3239158 | 0.86 | KDM1A (0.32) | BACE1 | |
| SCHEMBL3243471 | 0.84 | CYP2D6 (0.34) | PDK2IGF1R | |
| SCHEMBL3243724 | 0.83 | KDM1A (0.40) | BACE1 | |
| SCHEMBL3248669 | 0.82 | AAK1 (0.32) | PDK2 | |
| SCHEMBL3240569 | 0.82 | BACE1 (0.32) | BACE1 | |
| SCHEMBL3248214 | 0.81 | GALR3 (0.40) | PDK2 | |
| SCHEMBL3777045 | 0.77 | NPSR1 (0.30) | — | |
| SCHEMBL3245524 | 0.74 | HCAR2 (0.31) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | claimed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | claimed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | PSEN1, PSEN2, BACE1 | PDK2 1595/4885ADAM17 2206/4885SLC2A1 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.